Screener
Kyverna Therapeutics, Inc. KYTX Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromDebtNetOfIssuanceCosts.
The source filing: Kyverna Therapeutics, Inc.’s 10-K, filed March 26, 2026.
- Filed
- Mar 26, 2026, 4:11 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-126242
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock upon initial public offering and underwritten public offering, net of underwriting commissions | 98,968 | 341,171 |
| Proceeds from issuance of common stock under the ATM Facility, net of agent's fees | 16,940 | — |
| Proceeds from borrowing of the term loan, net of issuance costs | 24,700 | — |
| Proceeds from exercise of common stock options | 1,987 | 259 |
| Principal paid on finance lease liabilities | (808) | (956) |
| Payments for common stock issuance offering costs | (475) | (3,361) |
| Taxes paid related to net share settlement upon vesting of restricted stock units | (144) | — |
Item 16. Form 10-K Summary
FAQ
- What is Kyverna Therapeutics, Inc.'s debt issuance proceeds?
- Kyverna Therapeutics, Inc. (KYTX) reported debt issuance proceeds of $6.18M in Q4 2025.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Kyverna Therapeutics, Inc.'s debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude